Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, Rituximab, and Nivolumab in Richter's Transformation
NCT06247540Phase 2Withdrawn
- Sponsor
- Northwestern University
- Start
- Mar 2024
- Primary completion
- Dec 2029
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, nivolumab in Richter's transformation (RT), sponsored by Northwestern University. Planned start Mar 2024; status: withdrawn.
02
Drugs
venetoclaxnivolumab
03
Conditions
Richter's transformation (RT)
Beyond the preview
Go deeper on NCT06247540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06247540.